The Ministry of Health and Community Protection announced that the UAE is the second country in the world to approve the registration and use of the first and only drug “Adohelm – Aducanumab” for the treatment of early stages of Alzheimer’s disease, produced by the “Biogen” company, after its approval and approval by the US Food and Drug Administration “FDA”. The importance of registering this drug lies in giving priority to Alzheimer’s patients in the country and the countries of the region in obtaining this innovative drug to accelerate the treatment plan and improve their quality of life, within the framework of the UAE’s leadership globally to attract and provide innovative drugs that have proven their effectiveness, efficiency and approval within the treatment protocols, which contributes significantly to the development of the system health according to international best practices. The Ministry’s granting of approval to register the drug “Adohelm” as an injection at a dose of 100 mg for the treatment of Alzheimer’s patients who suffer from mild cognitive impairment or in the first stage of dementia by inhibiting “beta-amyloid” plaques in the brain within the framework of the “fast track drug registration” process within the category of innovative drugs And the first of its kind in the world in parallel with the keenness on the importance of early diagnosis and the development of medical practices in the field of Alzheimer’s disease to achieve social and psychological empowerment. His Excellency Abdul Rahman bin Muhammad Al Owais, Minister of Health and Community Protection, stressed that this qualitative achievement comes within the framework of the UAE’s keenness, according to the directives of the wise leadership, to consolidate its leadership and precedence in attracting and providing innovative medicines that have proven effectiveness, efficiency and approval within treatment protocols, in addition to the flexibility of supply chains and the development of the legislative structure that keeps pace with Developments in the pharmaceutical industry, which greatly contribute to accelerating the recovery of patients and improving their quality of life, which are among the priorities of the work of the Ministry and health authorities. His Excellency pointed out that the UAE is one of the fastest countries in the world in drug accreditation, which provides solutions to patients in the country and the region, which pushes the consolidation of the UAE’s competitive position in the global drug market to become a leading destination for international pharmaceutical companies and motivate them to choose the UAE as a center for marketing their new innovative products, which contributes to Enhancing the efficiency of the pharmaceutical system and establishing quality, therapeutic, health and drug safety systems in line with the vision of the UAE Centennial. For his part, His Excellency Dr. Muhammad Salim Al Olama, Undersecretary of the Ministry of Health and Community Protection and Chairman of the Board of Directors of the Emirates Health Services Corporation, pointed out the Ministry’s keenness to ensure early access to innovative modern medicines by facilitating the licensing procedures for innovative medicines according to a well-studied mechanism for drug evaluation and registration, in addition to training and guidelines for doctors about Appropriate use in order to advance health care and provide innovative treatment options. He stressed the ministry’s keenness to provide therapeutic and psychological services for people with Alzheimer’s disease, especially for the elderly over 65 years, as it is the most vulnerable group through specialized clinics, and to provide a supportive and stimulating environment for patients and community rehabilitation within the framework of the national mental health policy strategy to achieve social, psychological and professional empowerment of patients and to provide promotional services And treatment and rehabilitation of international standards. For his part, His Excellency Dr. Amin Hussein Al Amiri, Assistant Undersecretary for the Health Regulatory Sector, explained that the Ministry has an advanced mechanism in licensing and registering medicines in accordance with the best international standards and requirements in drug evaluation, which contributes to strengthening the leadership of the UAE in adopting and launching the latest pharmaceutical technologies to protect the health of society, which constitutes a map A road full of opportunities and challenges, which the Ministry is working on in cooperation with various stakeholders in terms of updating regulatory standards, licensing mechanisms and guidelines to support pharmaceutical and health technology companies. He noted that the UAE is characterized by the presence of the infrastructure and modern systems that help to invest in the pharmaceutical sector and encourage international companies to find their regional position and produce their innovative and similar medicines in the country, in light of the UAE government’s support for innovation and creativity, protecting intellectual property and encouraging investment in the health sector in general and the pharmaceutical sector in general. Special . He pointed out that the Ministry is working proactively in communicating with international companies for medicine and medical supplies to show recent innovations, even if they are within the scope of clinical studies, and work to attract them so that the UAE will be the first country in the world after accreditation by the US Food and Drug Authority “FDA”. For his part, Rashid Azar, Executive Vice President, Alzheimer’s and Cognitive Impairment Business Unit at Biogen, said: “Biogen’s tireless efforts to conduct research and dedication to achieving its goals have given us the ability to fulfill our commitment to provide the first treatment of its kind many years ago.” For Alzheimer’s patients.. We believe that this drug will give patients suffering from early-stage Alzheimer’s disease, their families and health care providers a new glimmer of hope, especially as they have been waiting for scientific progress in this regard for decades. He thanked the Ministry of Health and Community Protection in the country for its efficient response to the needs of Alzheimer’s patients and its rapid evaluation of the drug “Adohelm”. In turn, Dr. Paul Eisen, MD, director of the Alzheimer’s Disease Research Institute “ATRI”, University of Southern California, said that for the first time in history, we have been able to achieve an unprecedented achievement by moving beyond treating the symptoms of Alzheimer’s disease towards targeting the main causes of the disease. Early detection and diagnosis of mild cognitive impairment will allow us the possibility Determine which patients could benefit from this innovative treatment.
Leave a Reply